SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

Core Insights - SeaStar Medical Holding Corporation is set to report its first quarter financial results on May 14, 2025, after market close, followed by a webcast and conference call to discuss the results and business progress [1][2]. Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life [1][2]. - The company's first commercial product, QUELIMMUNE (SCD-PED), received FDA approval in 2024, specifically for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients [2]. - SeaStar's Selective Cytopheretic Device (SCD) therapy has been granted Breakthrough Device Designation by the FDA for six therapeutic indications, which may facilitate a faster approval process and better reimbursement conditions upon commercial launch [2]. - The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a condition affecting over 200,000 adults in the U.S. annually, with no effective treatment options available [2].